Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04795869
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:32.296564+00:00
Published At
2023-10-10T00:00:00+00:00
Record Updated At
2023-10-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Follicular T-Cell Lymphoma", "Recurrent Hepatosplenic T-Cell Lymphoma", "Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Follicular T-Cell Lymphoma", "Refractory Hepatosplenic T-Cell Lymphoma", "Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-10-10"
protocolSection.identificationModule.nctId
"NCT04795869"
protocolSection.identificationModule.officialTitle
"Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Angioimmunoblastic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Follicular T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Hepatosplenic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype (protocolSection.conditionsModule.conditions)
  • Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Angioimmunoblastic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Follicular T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Hepatosplenic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype (protocolSection.conditionsModule.conditions)
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.